News Releases

October 2020

October 8, 2020 10/8/2020 Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT forAlpha-1 Antitrypsin-Associated Liver Disease

September 2020

September 24, 2020 9/24/2020 Announcement of decision on a basic plan for a merger (simple merger/short-form merger) with a wholly owned subsidiary

September 18, 2020 9/18/2020 Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress

September 16, 2020 9/16/2020 Takeda to Divest TachoSil® to Corza Health for €350 Million

September 15, 2020 9/15/2020 Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs

September 9, 2020 9/9/2020 Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma

September 8, 2020 9/8/2020 Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD

August 2020

August 25, 2020 8/25/2020 Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome

August 24, 2020 8/24/2020 Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion